Difference between revisions of "Smoldering multiple myeloma"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:100%;" ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26" |'''Page editor''' ! col...") |
Tag: visualeditor-switched |
||
Line 47: | Line 47: | ||
===References=== | ===References=== | ||
# '''ECOG E3A06:''' Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2019 Oct 25:JCO1901740. [Epub ahead of print] [https://ascopubs.org/doi/full/10.1200/JCO.19.01740 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23958922 PubMed] | # '''ECOG E3A06:''' Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2019 Oct 25:JCO1901740. [Epub ahead of print] [https://ascopubs.org/doi/full/10.1200/JCO.19.01740 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23958922 PubMed] | ||
+ | |||
+ | |||
+ | ==Rd {{#subobject:bec321|Regimen=2}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | |||
+ | ===Regimen {{#subobject:45c352|Variant=1}}=== | ||
+ | {| class="wikitable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 25%"|Study | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 25%"|Comparator | ||
+ | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1300439 Mateos et al. 2013] | ||
+ | | style="background-color:#1a9851" |Phase III (E) | ||
+ | |[[#Observation|Observation]] | ||
+ | | style="background-color:#1a9850" |Seems to have superior OS | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: this trial did not require modern imaging modalities to rule out active myeloma, and therefore it is probable that many patients on this study had active as opposed to smoldering multiple myeloma.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | ||
+ | *[[Dexamethasone (Decadron)]] 20 mg PO once per day on days 1 to 4, 12 to 15 | ||
+ | |||
+ | ====Supportive medications==== | ||
+ | *[[Aspirin]] 100 mg PO once per day | ||
+ | |||
+ | '''28-day cycle for 9 cycles''' | ||
+ | |||
+ | ====Subsequent treatment==== | ||
+ | *[[#Lenalidomide_monotherapy|Lenalidomide maintenance]] | ||
+ | |||
+ | ===References=== | ||
+ | # Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439. PubMed PMID: 23902483. [https://www.nejm.org/doi/full/10.1056/NEJMoa1300439 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23902483 PubMed] | ||
==Observation== | ==Observation== | ||
Line 65: | Line 101: | ||
|[[#Lenalidomide_monotherapy|Lenalidomide]] | |[[#Lenalidomide_monotherapy|Lenalidomide]] | ||
| style="background-color:#d73027" |Inferior PFS | | style="background-color:#d73027" |Inferior PFS | ||
+ | |- | ||
+ | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1300439 Mateos et al. 2013] | ||
+ | | style="background-color:#1a9851" |Phase III (C) | ||
+ | |[[#Rd|Rd]] | ||
+ | | style="background-color:#d73027" |Seems to have inferior OS | ||
|- | |- | ||
|} | |} | ||
Line 71: | Line 112: | ||
===References=== | ===References=== | ||
# '''ECOG E3A06:''' Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2019 Oct 25:JCO1901740. [Epub ahead of print] [https://ascopubs.org/doi/full/10.1200/JCO.19.01740 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23958922 PubMed] | # '''ECOG E3A06:''' Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2019 Oct 25:JCO1901740. [Epub ahead of print] [https://ascopubs.org/doi/full/10.1200/JCO.19.01740 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23958922 PubMed] | ||
+ | # Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439. PubMed PMID: 23902483. [https://www.nejm.org/doi/full/10.1056/NEJMoa1300439 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23902483 PubMed] | ||
[[Category:Smoldering multiple myeloma regimens]] | [[Category:Smoldering multiple myeloma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Plasma cell dyscrasias]] | [[Category:Plasma cell dyscrasias]] |
Revision as of 15:14, 3 November 2019
Page editor | Section editor | ||
---|---|---|---|
Samuel M. Rubinstein, MD Vanderbilt University Nashville, TN rubinstein_md |
Andrew J. Cowan, MD University of Washington Seattle, WA andrewcowanmd |
4 regimens on this page
7 variants on this page
|
All lines of therapy
Lenalidomide monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Lonial et al. 2019 (ECOG E3A06) | Phase III (E) | Observation | Superior PFS |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Supportive medications
- Aspirin 325 mg PO once per day
28-day cycles
References
- ECOG E3A06: Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2019 Oct 25:JCO1901740. [Epub ahead of print] link to original article contains verified protocol PubMed
Rd
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Mateos et al. 2013 | Phase III (E) | Observation | Seems to have superior OS |
Note: this trial did not require modern imaging modalities to rule out active myeloma, and therefore it is probable that many patients on this study had active as opposed to smoldering multiple myeloma.
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 20 mg PO once per day on days 1 to 4, 12 to 15
Supportive medications
- Aspirin 100 mg PO once per day
28-day cycle for 9 cycles
Subsequent treatment
References
- Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439. PubMed PMID: 23902483. link to original article contains verified protocol PubMed
Observation
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Lonial et al. 2019 (ECOG E3A06) | Phase III (C) | Lenalidomide | Inferior PFS |
Mateos et al. 2013 | Phase III (C) | Rd | Seems to have inferior OS |
No treatment.
References
- ECOG E3A06: Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2019 Oct 25:JCO1901740. [Epub ahead of print] link to original article PubMed
- Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439. PubMed PMID: 23902483. link to original article contains verified protocol PubMed